Immunocompatibility Group

Led by Dr Neill Liptrott, the Immunocompatibility Group aims to understand the concepts and mechanisms which underlay the interface of advanced materials and complex medicines with the immune system; to support their translation to clinical use and gain insight into the fundamental biology behind them. To date, we have worked with a wide variety of nanotherapeutics from lipidic nanoparticles to polymeric and from virosomes to exosomes for the delivery of diagnostics, small molecules, biopharmaceuticals, biopolymers and nucleic acids. 

Dr Chris David

Chris developed experience in biochemistry, regenerative medicine, and nanotoxicology, having gained his BSc in Medical Biochemistry and MSc in Nanomedicine before joining University of Liverpool to undertake his PhD. His research investigated biocompatibility and immunological safety of conventional and nanotechnology-enabled medicines as well as cellular therapies to better inform the assessment methodologies used for biologically applied nanotechnologies.

Danielle Brain

Danielle obtained her undergraduate degree in Pharmacology before undertaking her PhD working on an NIH funded grant focussing on improving the assays that are used to assess the immunocompatbility of novel long-acting formulations and more specifically those designed to be administered subcutaneously. Danielle explored the role of the inflammasome in mediating immunological responses to these long-acting formulations and the role the inflammasome plays in COVID-19 infection.

Alex Plant-Hately

Alex obtained his BSc in Pharmacology before earning his Master’s in Nanomedicine and has since started working towards a PhD, exploring the immune responses related to the use of nanoparticles within pharmaceutical formulation. This focused on the use of liposomes as drug delivery vehicles, and their relation to anaphylaxis-like adverse drug responses which is the same nanotechnology used in various COVID-19 vaccinations.

Beth Heaton

Beth completed her undergraduate degree in Biochemistry and an MRes degree which investigated the impact of HIV antiretrovirals on glucose uptake and immune cell activation. She then began working towards a PhD investigating the interactions of nano-enabled medical technologies with components of the human immune and haematological systems, looking more specifically into the biocompatibility of these materials with the immune system. Her project investigated the impact of how long these nano-enabled materials remain in place and how this affects their clinical utility.

Back to: Centre of Excellence for Long-acting Therapeutics